Biotech entity
All 2 tracked stories fall under one category: pharma. 340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 7-day window averages about 2 stories each week. At 6, the average consequence score sits above the same-window beat average of 5.7.
Last mentioned: Aug 7, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. 340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 7-day window averages about 2 stories each week. At 6, the average consequence score sits above the same-window beat average of 5.7. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. generic drugs appears in 2 tracked Biotech stories published from August 1, 2026 through August 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 62 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering generic drugs. Shared-story counts are live from our verified record — not editorial picks.
Tariff Escalates to 200%
The tariff rate doubles to 200% on generic drug imports.
100% Tariff Takes Effect
A 100% duty is imposed on eligible generic drug imports.
Duty‑Free Period Begins
Imported generics enter a two‑year duty‑free window.
Generic Drug Tariff Schedule Announced
The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
Executive Order Tariffs Patented Medicines
President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.
The tariff escalation to 200% on generic drugs by August 2029 also applies to biosimilars, which were initially exempt. For biotech and pharma, this could disrupt outsourcing strategies and market access for follow-on biologics. The timeline analysis details product-level risks.
The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Source: heraldglobe.com · milwaukeesun.com
generic drugs is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
